DL
David Lebwohl
EVP, Chief Medical Officer

David Lebwohl insider trades: Intellia Therapeutics (NTLA) stock sales

EVP, Chief Medical Officer, Intellia Therapeutics Last trade Jan 5, 2026 20 Form 4 filings
$110K
Sold, last 12 months
1 sale
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2021
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where David reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 5, 2026NTLA↓ Sell$110K
Jan 3, 2025NTLA↓ Sell$116K
Jan 3, 2024NTLA↓ Sell$172K
Jan 4, 2023NTLA↓ Sell$96K
Jan 1, 2022NTLA↓ Sell$118K
Nov 5, 2021NTLA↓ Sell$319K
Oct 14, 2021NTLA↓ Sell$308K
Sep 21, 2021NTLA↓ Sell$360K
Aug 30, 2021NTLA↓ Sell$379K
Aug 9, 2021NTLA↓ Sell$394K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other NTLA insiders

Open-market trades in the last 12 months

About David Lebwohl's insider trades

David Lebwohl is EVP, Chief Medical Officer at Intellia Therapeutics (NTLA). Since Aug 9, 2021, David has reported no open-market purchases and 10 sales worth $2.4M on SEC Form 4. In the last 12 months: 1 sale ($110K).

Their filings also include option exercises (10 filings), grants and awards (7 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NTLA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.